Thewaico Launched Three Bioreactor Platforms
The company introduced modular systems and AI process control to bridge the gap between lab-scale and industrial production.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you believe new biomanufacturing technology will make sustainable food and materials more affordable?
Thewaico has emerged from stealth to launch three new bioreactor platforms—GECKO, SPIRIT, and JUMBO—alongside its STRYPES AI-assisted process control software. These systems are designed to provide a continuous path for scaling biological processes from benchtop volumes to industrial production.
Why it matters
The synthetic biology industry has lost an estimated $8 to $12 billion over the past 15 years due to failures in scaling processes, a problem exacerbated by legacy pharmaceutical systems unsuited for newer applications like biofertilizers or cultivated meat. Standardizing this path is critical to meeting a projected demand of 10 billion liters of capacity by 2030.
The GECKO platform manages up to 32 units in a single environment with capacities from 2 to 10 liters, while the SPIRIT platform covers 30 to 300 liters. This modular architecture aims to address the current bottleneck of having only 10 million liters of unreserved capacity out of 61 million liters globally.
The players
Thewaico
A biotech firm with headquarters in Rovereto, Italy and Emeryville, California, focused on modular bioreactor hardware and AI-driven process control.
The details
Thewaico’s platforms utilize a digital-first commercial model that allows customers to configure bioreactor systems and obtain pricing directly online. By integrating STRYPES, an AI-assisted process control software, the hardware is intended to maintain consistent environmental parameters as volumes increase. This architecture specifically targets the transition from small-scale laboratory trials to industrial manufacturing, replacing the disjointed systems that often cause failure during process scale-up.
Timeline
Over the past 15 years, synthetic biology firms have absorbed $8 to $12 billion in losses related to scaling.
Thewaico launched its bioreactor platforms and control software on October 1, 2026.
Projected food-sector bioreactor demand is expected to reach 10 billion liters by 2030.
The Tech Race
Thewaico is entering a market defined by the massive $8 to $12 billion in losses sustained by the synthetic biology sector over the last 15 years. Their platforms aim to resolve these failures by replacing legacy systems that lack a clear, continuous path from research benches to mass production.
Researchers and industrial developers can now access an online portal to configure bioreactor systems and obtain pricing without traditional sales cycles. This digital model provides immediate access to hardware specifications for the GECKO and SPIRIT platforms, enabling faster planning for pilot and production workflows.
The takeaway
Thewaico aims to solve the industry-wide bottleneck that has seen billions in potential value lost during the transition from lab to factory. Watch for the company's progress in capturing the 10 million liters of currently unreserved global capacity as they deploy their platforms through 2030.
Further reading
Explore more on the shift toward scalable industrial biology in the Biotech section.
More information
To configure systems or review platform pricing, visit the Thewaico customer configuration inquiry portal.
Source note: This article includes information reported by Pharmaceutical-tech.
Live Poll
Do you believe new biomanufacturing technology will make sustainable food and materials more affordable?
